NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Shareholders of Cellebrite DI Ltd. (NASDAQ: CLBT) took losses when the stock sold off following the Company's Q2 2026 results, which included revenue of approximately $131.1 million -- below analyst consensus -- and a reduction to full-year 2026 annual recurring revenue and revenue guidance. If you held CLBT shares through that decline, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The loss impact stacked on multiple fronts in a single report. Revenue came in under Street estimates. Quarterly ARR fell shy of internal projections. Full-year 2026 ARR and revenue guidance were cut. Q3 2026 revenue guidance was set below consensus as well. Management pointed to longer sales cycles and a “meaningful acceleration” that “did not materialize at the level [they had] anticipated.” The completion of the company’s planned CEO succession also was announced, with the recently appointed president, Shiven Ramji, taking over the role immediately.
Levi & Korsinsky is investigating potential securities law violations on behalf of CLBT shareholders who suffered losses. Shareholders who lost money on Cellebrite DI are encouraged to have their losses reviewed at no cost or call (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the CLBT Investigation
Q: How much did CLBT stock drop? A: Shares declined over 30% by midday trading after the Company reported Q2 2026 revenue of approximately $131.1 million, below consensus; ARR of $507.8 million, below company guidance; and lowered its full-year 2026 ARR and revenue guidance while issuing a below-consensus Q3 outlook. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: Who is eligible to participate in the CLBT investigation? A: Investors who purchased CLBT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Cellebrite DI made materially false or misleading statements regarding its ARR growth trajectory, revenue outlook, and expected expansion from Inseyets conversions. When the Company reported Q2 2026 results and reduced its full-year 2026 guidance, the stock price declined.
Q: What do CLBT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my CLBT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CLBT and sold at a loss may still participate in the investigation.
Q: What if my CLBT losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
